Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937996 · ClinicalTrials.gov registry record
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
A clinical trial of Pancreatic Cancer Non-resectable, sponsored by Englewood Hospital and Medical Center.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06937996 is a study of Pancreatic Cancer Non-resectable that is actively recruiting participants, run by Englewood Hospital and Medical Center. The registered enrollment target is 25 participants, below the 38-participant average among 4 other Pancreatic Cancer Non-resectable trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06937996, a study of Pancreatic Cancer Non-resectable, is actively recruiting participants, sponsored by Englewood Hospital and Medical Center.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.
Conditions Studied
Interventions
- DEVICE NanoKnife
Study Locations (1)
New Jersey
- Englewood Hospital - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2035-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06937996
The ClinicalTrials.gov registry entry for NCT06937996 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 4 other Pancreatic Cancer Non-resectable trials with a reported enrollment target (34% lower). The listed sponsor is Englewood Hospital and Medical Center, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer Non-resectable appearing as the primary indexed condition, and to 1 intervention - of which NanoKnife is the first listed.
NCT06937996 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06937996 about?
NCT06937996 is a clinical study titled "Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-". The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresect...
What is the current status of trial NCT06937996?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2025-05-13. Estimated completion is 2035-05-31.
What conditions does trial NCT06937996 study?
This clinical trial studies the following conditions: Pancreatic Cancer Non-resectable.
What interventions are being tested in trial NCT06937996?
The interventions under investigation include: NanoKnife (DEVICE).
Who is sponsoring clinical trial NCT06937996?
This trial is sponsored by Englewood Hospital and Medical Center, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937996 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer Non-resectable
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 1
-
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.